Back to search results

Study of Endocrine Therapy for Lobular Breast Cancer

This study is looking at how well endocrine therapy, given before surgery, works for postmenopausal women with a specific type of breast cancer called invasive lobular carcinoma (ILC). The endocrine therapies being studied are anastrozole, letrozole, exemestane, or tamoxifen. You may be able to join if you are a woman aged 50 or older, have ILC that is HER2-negative and ER-positive (meaning your cancer cells have certain characteristics), and are planning to have breast-conserving surgery. The main goal is to see if this treatment reduces the chance of having cancer cells at the edges of the tissue removed during surgery. The study aims to enroll 176 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 176 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, the rate of positive surgical margins, is measured at up to 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07483307

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Recruiting
PHASE2Ages 50+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~176 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Neoadjuvant endocrine therapy

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of positive surgical margins after breast cancer surgery
Measured over up to 3 months

Conditions

Breast Cancer
HER2-negative Breast Cancer
HER2 Negative Breast Carcinoma
ER+ Breast Cancer
Lobular Breast Carcinoma

Explore related trials

Invasive Breast Lobular Carcinoma

NCT07483307

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

    Commack, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Anita SKCCSC(P Mamtani, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Anita Mamtani, MD
[email protected]
646-888-6864
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent by participant or legally authorized representative
Postmenopausal women aged ≥50 years with biopsy-proven cT2-T3 N0-1 ILC who opt to undergo and are medically fit to undergo BCS at enrollment.
Tumors of the ER+/HER2- subtype, defined as:

Exclusion

Patients with prior ipsilateral breast cancer.
Patients with advanced regional disease (cN2/cN3) or stage 4 disease.
Patients who would benefit from neoadjuvant chemotherapy, per the treating medical oncologist.
Patients who are not candidates for definitive breast surgery (inoperable or stage 4 disease).
Patients with gadolinium allergy, precluding the use of breast MRI.

What this trial measures

  • Rate of positive surgical margins after breast cancer surgeryup to 3 months

    To prospectively evaluate rates of positive surgical margins after initial breast cancer surgery/BCS among postmenopausal women with cT2-3 N0-1 ER+/HER2- ILC who have undergone a course of NET.